



Visit www.thyroid.org to learn more about the ATA, our services, clinical management guidelines & upcoming programs.

Program Description:

Thyroid nodules are a common clinical problem, and differentiated thyroid cancer (DTC) is becoming increasingly prevalent. A large amount of new information and evidence grading processes has become available since the 2009 guidelines. This has prompted the American Thyroid Association (ATA) to develop new and updated evidence-based recommendations to assist in the clinical management of patients with thyroid nodules and DTC. Authors from the international community of thyroid specialists in endocrinology and surgery will discuss recently published guidelines with special focus on:

- Case based applications of the revised guidelines;
- New guidelines in 2014; and
- Contemporary optimal care for patients with thyroid nodules and differentiated thyroid cancer.

Agenda:

12:30 PM – 12:35 PM	<p>Welcome and Introductions <i>Bryan R. Haugen, MD, University of Colorado School of Medicine</i></p>
12:35 PM – 12:45 PM	<p>Process of Development and Format of the 2014 Nodules/DTC Guidelines <i>Bryan R. Haugen, MD</i></p>
12:45 PM – 1:00 PM	<p>Approaches to Patients with Thyroid Nodules Use of Neck Ultrasound to Guide Fine Needle Aspiration Decision-Making <i>Susan J. Mandel, MD, University of Pennsylvania</i></p>
1:00 PM – 1:15 PM	<p>Cytologic and Surgical Pathology Considerations <i>Yuri Nikiforov, MD, PhD, University of Pittsburgh Medical Center</i></p>
1:15 PM – 1:30 PM	<p>Use of Molecular Markers to Guide Decision-Making <i>David L. Steward, MD, University of Cincinnati</i></p>
1:30 PM – 1:50 PM	<p>Questions and Answers</p>
1:50 PM – 2:05 PM	<p>Approaches to Initial Therapy for Differentiated Thyroid Cancer Preoperative Disease Mapping and Voice Assessment <i>Gregory W. Randolph, MD, Massachusetts Eye and Ear Infirmary</i></p>
2:05 PM – 2:20 PM	<p>Surgical Approach and Considerations <i>Julie Ann Sosa, MD, Duke University School of Medicine</i></p>
2:20 PM – 2:35 PM	<p>Staging and Risk Stratification Updates <i>Erik K. Alexander, MD, Brigham & Women's Hospital</i></p>
2:35 PM – 2:50 PM	<p>Updates on Radioactive Iodine Use – Consideration, Dosing, Preparation <i>Anna M. Sawka, MD, Toronto General Hospital</i></p>
2:50 PM – 3:05 PM	<p>Integrating Response to Therapy in Monitoring Management <i>R. Michael Tuttle, MD, Memorial Sloan-Kettering Cancer Center</i></p>
3:05 PM – 3:25 PM	<p>Questions and Answers</p>
3:25 PM – 3:45 PM	<p>BREAK</p>
3:45 PM – 4:00 PM	<p>Approaches to Patients with Advanced DTC Monitoring and Directed Therapy for Radioactive Iodine-Refractory DTC <i>Furio Pacini, MD, University of Siena</i></p>
4:00 PM – 4:15 PM	<p>Systemic Therapy and Clinical Trials for Radioactive Iodine-Refractory DTC <i>Keith C. Bible, MD., PhD, Mayo Clinic</i></p>
4:15 PM – 4:30 PM	<p>Questions and Answers</p>
4:30 PM – 5:20 PM	<p>Case-Based Discussion on Practical Applications of the 2014 Nodules/DTC Guidelines <i>Bryan R. Haugen, MD/Panel (comprised of speakers noted above)</i></p>